A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
Status:
Terminated
Trial end date:
2020-08-24
Target enrollment:
Participant gender:
Summary
This is an open label Phase 2, 2-stage, 2-cohort study to evaluate rucaparib in combination
with nivolumab in patients with high-grade serous or endometroid ovarian cancer.
Patients entering the following cohorts must have BRCA mutational status confirmed by a
central lab:
- Cohort A1: No BRCA mutation in tumor; high level of LOH (loss of heterozygosity)
- Cohort A2: BRCA mutation in tumor